-+ 0.00%
-+ 0.00%
-+ 0.00%

Evommune shares plummeted 11.3% as its eczema drug failed to reach a major end in mid-term clinical trials.

Zhitongcaijing·09/09/2026 13:57:10
Listen to the news
Evommune shares plummeted 11.3% as its eczema drug failed to reach a major end in mid-term clinical trials.